Shares of AcelRx Pharmaceuticals Inc. (ACRX) were down more than 27% in extended trading on Monday after the company revealed that its request for a Type B meeting with the FDA, to clarify the agency’s belief that an additional clinical study is needed in order to approve Zalviso, has been denied.